Phospholipid Cyclosporine Prodrugs Targeted at Inflammatory Bowel Disease (IBD) Treatment: Design, Synthesis, and in Vitro Validation.


Journal

ChemMedChem
ISSN: 1860-7187
Titre abrégé: ChemMedChem
Pays: Germany
ID NLM: 101259013

Informations de publication

Date de publication:
03 09 2020
Historique:
received: 11 05 2020
revised: 26 06 2020
pubmed: 4 7 2020
medline: 16 6 2021
entrez: 4 7 2020
Statut: ppublish

Résumé

Novel phospholipid (PL)-cyclosporine conjugates were prepared and studied as potential prodrugs for inflammatory bowel disease (IBD). Our approach relies on phospholipase A

Identifiants

pubmed: 32618133
doi: 10.1002/cmdc.202000317
doi:

Substances chimiques

Phospholipids 0
Prodrugs 0
Cyclosporine 83HN0GTJ6D
Phospholipases A2 EC 3.1.1.4

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1639-1644

Informations de copyright

© 2020 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Références

N. J. Lowe, N. Engl. J. Med. 1991, 324, 333-334.
A. J. Meyrier, Nephrol. 1997, 10, 14-24.
W. J. Sandborn, W. J. Tremaine, Mayo Clin. Proc. 1992, 67, 981-90.
D. Tedesco, L. J. Haragsim, Transplant. 2012, 230386-230386.
A. W. Thomson, G. H. Neild, BMJ (Clinical research ed.) 1991, 302, 4.
G. Wells, D. Haguenauer, B. Shea, M. E. Suarez-Almazor, V. A. Welch, P. Tugwell, Syst. Rev. 2000, 001083.
J. F. Elliott, Y. Lin, S. B. Mizel, R. C. Bleackley, D. G. Harnish, V. Paetkau, Science 1984, 226, 1439-41.
S. Lichtiger, D. H. Present, A. Kornbluth, I. Gelernt, J. Bauer, G. Galler, F. Michelassi, S. Hanauer, N. Engl. J. Med. 1994, 330, 1841-5.
N. Narula, J. K. Marshall, J. F. Colombel, G. I. Leontiadis, J. G. Williams, Z. Muqtadir, W. Reinisch, J. Gastroenterol. 2016, 111, 477-91.
T. B. Strom, R. Loertscher, N. Engl. J. Med. 1984, 311, 728-729.
A. K. Waljee, W. L. Wiitala, S. Govani, R. Stidham, S. Saini, J. Hou, L. A. Feagins, N. Khan, C. B. Good, S. Vijan, P. D. R. Higgins, PLoS One 2016, 11, 158017-0158017.
T. Zenlea, M. A. Peppercorn, World J. Gastroenterol. 2014, 20, 3146-3152.
S. C. Ng, H. Y. Shi, N. Hamidi, F. E. Underwood, W. Tang, E. I. Benchimol, R. Panaccione, S. Ghosh, J. C. Y. Wu, F. K. L. Chan, J. J. Y. Sung, G. G. Kaplan, Lancet 2017, 390, 2769-2778.
O. Olen, J. Askling, M. C. Sachs, P. Frumento, M. Neovius, K. E. Smedby, A. Ekbom, P. Malmborg, J. F. Ludvigsson, J. Gastro. 2019, 156, 614-622.
A. Dahan, G. L. Amidon, E. M. Zimmermann, Expert Rev. Clin. Immunol. 2010, 6, 543-50.
F. Kesisoglou, E. M. Zimmermann, Expert Opin. Drug Delivery 2005, 2, 451-63.
O. Wolk, S. Epstein, V. Ioffe-Dahan, S. Ben-Shabat, A. Dahan, Expert Opin. Drug Delivery 2013, 10, 1275-1286.
J. Rautio, N. A. Meanwell, L. Di, M. J. Hageman, Nat. Rev. Drug Discovery 2018, 17, 559-587.
S. Amidon, J. E. Brown, V. S. Dave, AAPS PharmSciTech 2015, 16, 731-741.
M. Iacucci, S. de Silva, S. Ghosh, Can. J. Gastroenterol. 2010, 24, 127-133.
M. M. Haapamaki, J. M. Gronroos, H. Nurmi, K. Alanen, M. Kallajoki, T. J. Nevalainen, Gut 1997, 40, 95-101.
M. M. Haapamaki, J. M. Gronroos, H. Nurmi, K. Alanen, T. J. Nevalainen, J. Gastroenterol. 1999, 94, 713-20.
M. M. Haapamaki, J. M. Gronroos, H. Nurmi, K. Irjala, K. A. Alanen, T. J. Nevalainen, Scand. J. Clin. Lab. Invest. 1999, 59, 279-87.
I. Lilja, K. Smedh, G. Olaison, R. Sjodahl, C. Tagesson, C. Gustafson-Svard, Gut 1995, 37, 380-5.
T. Minami, H. Tojo, Y. Shinomura, Y. Matsuzawa, M. Okamoto, Gut 1994, 35, 1593-8.
N. S. Yarla, A. Bishayee, L. Vadlakonda, R. Chintala, G. R. Duddukuri, P. Reddanna, K. S. Dowluru, Curr. Drug Targets 2016, 17, 1940-1962.
A. Dahan, R. Duvdevani, I. Shapiro, A. Elmann, E. Finkelstein, A. Hoffman, J. Controlled Release 2008, 126, 1-9.
M. Kurz, G. K. Scriba, J. Chem. Phys. Lip. 2000, 107, 143-57.
A. Dahan, S. Ben-Shabat, N. Cohen, S. Keinan, I. Kurnikov, A. Aponick, E. M. Zimmermann, Curr. Top. Med. Chem. 2016, 16, 2543-8.
A. Dahan, R. Duvdevani, E. Dvir, A. Elmann, A. Hoffman, J. Controlled Release 2007, 119, 86-93.
A. Dahan, M. Markovic, S. Epstein, N. Cohen, E. M. Zimmermann, A. Aponick, S. Ben-Shabat, Eur. J. Pharm. Sci. 2017, 108, 78-85.
A. Dahan, M. Markovic, S. Keinan, I. Kurnikov, A. Aponick, E. M. Zimmermann, S. Ben-Shabat, J. Comput.-Aided Mol. Des. 2017, 31, 1021-1028.
M. Markovic, A. Dahan, S. Keinan, I. Kurnikov, A. Aponick, E. M. Zimmermann, S. Ben-Shabat, Pharmaceutics 2019, 11.
I. Avan, S. R. Tala, P. J. Steel, A. R. Katritzky, J. Org. Chem. 2011, 76, 4884-4893.
T. Abe, K. Sakamoto, H. Kamohara, Y. Hirano, N. Kuwahara, M. Ogawa, Int. J. Cancer. 1997, 74, 245-50.
M. Markovic, S. Ben-Shabat, S. Keinan, A. Aponick, E. M. Zimmermann, A. Dahan, Pharmaceutics 2018, 10, 210.
W. Pruzanski, P. Vadas, E. Stefanski, M. B. Urowitz, J. Rheumatol. 1985, 12, 211-216.

Auteurs

Jagadeesh Nagendra Manda (JN)

Florida Center for Heterocyclic Compounds & Department of Chemistry, University of Florida, Gainesville, FL 32611, USA.

Milica Markovic (M)

Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, 84105, Israel.

Ellen M Zimmermann (EM)

Division of Gastroenterology, University of Florida, Gainesville, FL 32608, USA.

Shimon Ben-Shabat (S)

Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, 84105, Israel.

Arik Dahan (A)

Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, 84105, Israel.

Aaron Aponick (A)

Florida Center for Heterocyclic Compounds & Department of Chemistry, University of Florida, Gainesville, FL 32611, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH